Further development and use of sacroiliac joint devices becomes the…
Cape Coral, FL (Profitable.com) Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) is please to announce the details of the previously mentioned strategic transaction it has been negotiating. Nature’s was able to enter into a contractual obligation which gives it the rights to purchase an amazing formula for diabetes. Nature’s has tendered a deposit against formal closing, which is expected in the very near future. At the request of the inventor, to protect his privacy, financial terms are not to be disclosed in press releases.
The global diabetic drug market currently exceeds 25 billion dollars per year. The International Diabetes Federation estimated the global healthcare expenditures to treat and prevent diabetes and its complications are expected to total at least 376 billion dollars for 2010 and account for 11.6% of the total healthcare expenditures in the world.
Robert deZanger, CEO of Nature’s Bioceuticals reiterates his previous statement: “The implications of this natural medicine formula are mind boggling both in terms of the increased quality of life to the people who need it and the potential revenues to the company. There are over 20 different prescription drugs for this condition currently on the market and many of them have multi-billion dollar annual sales. We are anxious to have the formal closing and transfer of the rights as soon as possible so we can file a patent on the formula. We will then immediately start clinical trials to validate the veracity of the initial study. If the new expanded control group responds in a similar manner to the initial result this should be a product that will have far reaching implications and should generate acquisition interest from the major pharmaceutical and natural product companies.”
About Nature’s Bioceuticals
Nature’s Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature’s Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today’s prescribed drugs.
Nature’s line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as “DSHEA.”
In addition to historical information, this release contains forward-looking statements.
Mistral Ventures, Inc. and/or Nature’s Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature’s Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as “expects,” “intends,” “believes,” “anticipates,” “should,” “likely,” and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature’s Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company’s financial statements by the Company and its Audit Committee; modification of the Company’s accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.
Phone Number: 888 656 3509